Kynam Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kynam Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,094,620	Closed	-$119M	–	37
2023 Q1	$119M	Sell	1,094,620 -5,380	-0.5%	-$595K	15.42%	2
2022 Q4	$125M	Buy	+1,100,000	New	+$91.4M	19.2%	1

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Kynam Capital Management's HZNP Position: Q2 2023 in Review

Kynam Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 1,094,620 shares — an estimated $119M sold.

Kynam Capital Management first reported a position in HZNP in Q4 2022 and held it in 2 quarters. The position peaked at $125M in Q4 2022. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Kynam Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Kynam Capital Management sold 1,094,620 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $119M.
Kynam Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 2 quarters.
Kynam Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $125M in Q4 2022.
517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Kynam Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.